High PD-L1 and LC3B expression were associated with worse outcomes suggesting potential prognostic value and raise the hypothesis that concurrent targeting of autophagy and immune checkpoint pathways could provide therapeutic benefit in glioblastoma, warranting further preclinical and clinical investigation. Here, MAP1LC3B is linked to glioblastoma.